Dr. Rami Lehtinen nominated as CEO Injeq is shifting gears for market entry in summer 2018

Following the successful crowdfunding share issue in the second quarter of 2017 Injeq has shifted its focus from R&D to market entry. Three key elements are contributing to this target; the company is building up its production capacity in Tampere, ramping up the sales function and working rigorously towards CE approval for Injeq IQ-Needle™ product family. At the same time clinical trials are expanding to Sweden, Norway and Denmark.

Changing the operating mode of the company is a pivotal point, in which it is natural to change the captain of the boat as well. Kai Kronström has successfully led the company since its inception in December 2010. Kai is now handing the rudder over to Dr. Rami Lehtinen who has been VP Clinical Development & Sales in Injeq since January 2017.
“Kai together with the whole team has done tremendous work in taking us from day one to this point when we have a product ready to be introduced to the market. And now, it is a pleasant challenge for me to take our product into production and out to the market, where it can be used to improve patient safety and treatment outcome”, says Dr. Rami Lehtinen, CEO of Injeq.
“With funding from the successful crowdfunding share issue last summer Injeq is changing its key focus from R&D to market entry. At this stage it feels natural to also change the person at the helm of the company. Rami is a perfect choice to take us to the next level”, says Dr. Tommi Rasila, Chairman of Injeq.

Kai Kronström, one of the founders, will continue to work for Injeq with focus on the processes critical for timely market entry, such as the CE mark and product approvals.

Earlier this fall also the chairman of the board was changed when Chairman and Founder Prof. Jari Hyttinen took a position abroad. He was superseded by Dr. Tommi Rasila, who has been serving as the Vice-Chairman since fall 2016.

For further information meet Injeq at jENS 2017 in Venice or contact:
• Rami Lehtinen, CEO, +358 50 528 7012, rami.lehtinen@injeq.com
• Tommi Rasila, Chairman of the Board, +358 40 750 8158, tommi.rasila@injeq.com
• Photographs can be downloaded from https://injeq.com/media/

Injeq in brief:
Injeq is a medical device company based in Tampere, Finland. The company is devoted to developing and commercializing real-time bioimpedance based tissue identification. It has announced the first product currently in clinical trials; Injeq IQ-Needle™. Commercial availability for first products is planned for summer 2018. The technology can be applied for multiple clinical applications, including regional anesthesia, lumbar punctures, biopsy and intratumoral drug delivery. The products are expected to benefit the patients by improving diagnosis, reducing complications and enabling new type of treatments.

Injeq IQ-Needle™ – The smart needle that knows where its tip is.

Injeq is participating in Congress of Joint European Neonatal Societies #jENS

Injeq is participating in Congress of Joint European Neonatal Societies #jENS. Our Chief Scientific Officer Dr. Harri Sievanen is presenting (poster 132). […]
Read more »

Injeq quality management system is now MDR 2017/745 and ISO 13485 certified

According to the Medical Device Regulation 2017/745 (MDR) all medical device manufacturers must have a Quality Management System. Injeq Oy […]
Read more »

Injeq Oy:n laatujärjestelmälle on myönnetty lääkinnällisten laitteiden luokan I ja IIa MDR sekä ISO 13485 -sertifikaatit

Lääkinnällisiä laitteita koskevan EU-asetuksen 2017/745 (Medical Device Regulation, MDR) mukaan kaikilla lääkinnällisten laitteiden valmistajilla on oltava laadunhallintajärjestelmä. Injeq Oy:lle on […]
Read more »

47th Annual Meeting of the Society for Neonatology and Paediatric Intensive Care (GNPI), 16 June 2021

Injeq IQ-Tip® system present at virtual 47th Annual Meeting of the Society for Neonatology and Paediatric Intensive Care (GNPI)
Read more »

Visit us at SIOP Europe 2021!

Stay up-to-date with the newest technology in performing the challenging lumbar punctures in pediatric leukemia patients. Take advantage of our […]
Read more »

2nd Annual Meeting of the European Society for Paediatric Oncology, 28 April 2021

Injeq IQ-Tip® system present at virtual SIOPE congress 28.-30. April 2021
Read more »